首页> 外文期刊>Japanese Journal of Ophthalmology >Pars plana vitrectomy with removal of posterior hyaloid face in treatment of refractory diabetic macular edema resistant to triamcinolone acetonide.
【24h】

Pars plana vitrectomy with removal of posterior hyaloid face in treatment of refractory diabetic macular edema resistant to triamcinolone acetonide.

机译:帕氏玻璃体玻璃体切除术并去除玻璃样后脸,以治疗难治性丙酮酸曲安奈德的难治性糖尿病性黄斑水肿。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Triamcinolone acetonide (TA) has recently been used to treat diabetic macular edema (DME) but its effectiveness is limited. CASES: Three patients (three eyes) with unresolved diffuse DME who did not respond to a posterior sub-Tenon's injection of TA underwent vitrectomy. OBSERVATIONS: Intraoperatively, it was found that all of the eyes had a posterior hyaloid face that was adherent to a large area of the posterior pole retina, although this had not been detected by slit-lamp biomicroscopy or optical coherence tomography. After vitrectomy and removal of the posterior hyaloid face, there was a significant reduction in the central macular thickness of all three eyes and an improvement in the visual acuity of the patients. CONCLUSIONS: When TA treatment is not effective for DME, vitrectomy with the complete removal of the posterior hyaloid face, including removal of the internal limiting membrane, should be considered.
机译:背景:曲安奈德(TA)最近已用于治疗糖尿病性黄斑水肿(DME),但其效果有限。案例:3例(三眼)未解决的弥漫性DME患者对特农后路TA注射无反应,进行了玻璃体切割术。观察:术中发现,尽管裂隙灯生物显微镜或光学相干断层扫描法未检测到,但所有眼睛的后透明样面部均附着在大面积的后极视网膜上。玻璃体切除术和后玻璃样面部切除后,所有三只眼的中央黄斑中心厚度均明显减少,患者的视敏度得到改善。结论:当TA治疗对DME无效时,应考虑玻璃体切除术同时彻底清除玻璃体后玻璃体面部,包括去除内部限制膜。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号